2000 SIERRA POINT PARKWAY, BRISBANE, CA
Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Material disclosure
Tempest Therapeutics Enters Securities Purchase Agreement for $3.1M
Departure of Principal Financial Officer; Nicholas Rossettos Appointed CFO
Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics Enters $50 Million Purchase Agreement with Lincoln Park
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-1
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
S-8 POS
Correspondence
Submission Upload